Liver X receptors induce antiproliferative effects in basal-like breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Regulation

Background:

• Liver X receptors (LXRs) are key regulators of lipid metabolism and possess antiproliferative properties.
• Their therapeutic potential is being explored in cancers lacking targeted treatments, including triple-negative breast cancer.
• Understanding LXR agonist efficacy in breast cancer models is crucial for developing novel therapies.

Purpose of the Study:

• To investigate the effects of LXR agonists, alone and with carboplatin, on breast cancer preclinical models.
• To identify molecular mechanisms underlying LXR agonist activity in different breast cancer subtypes.
• To evaluate the potential of LXR agonists as a therapeutic strategy for breast cancer.

Main Methods:

• In vitro studies on estrogen receptor-positive breast cancer cells.
• In vivo studies on basal-like breast cancer models, combining LXR agonists with carboplatin.
• Functional proteomic and pathway analyses to identify molecular targets and pathways.

Main Results:

• LXR agonists demonstrated a dose-dependent decrease in tumor cell proliferation in vitro.
• In vivo, LXR activation combined with carboplatin showed enhanced growth inhibition in basal-like breast cancer models.
• Proteomic analysis revealed differences in Akt activity, cell-cycle progression, and DNA repair proteins between responding and nonresponding models.

Conclusions:

• LXR agonists, especially in combination with carboplatin, exhibit therapeutic promise for basal-like breast cancer.
• The combination therapy impacts E2F transcription factor targets and cholesterol homeostasis.
• Further research into LXR-targeted therapies is warranted for challenging breast cancer types.